- Bespak has issued its first Environmental, Social and Governance (ESG) update, outlining early achievements and future sustainability plans.
- The inhalation-focused CDMO aims to support the pharmaceutical industry’s transition to low carbon solutions, including greener pMDIs.
Bespak, a specialist inhalation contract development and manufacturing organisation (CDMO), has published its first Environmental, Social and Governance (ESG) update. The report outlines the company’s progress in embedding sustainability across its operations and value chain during its first year.
The update details several completed milestones, including the development of an ESG strategy, a double-materiality assessment, stakeholder mapping, verified baseline data on scope 1 and 2 greenhouse gas emissions, and the establishment of an ESG & Enterprise Risk Governance Framework. The initiative aligns with growing regulatory pressures and industry-wide commitments to lower environmental impact.
The CDMO is focused on enabling the shift to low carbon pressurised Metered Dose Inhalers (pMDIs) while also implementing broader environmental initiatives. According to the company, ESG integration is part of a wider plan to increase transparency and accountability in its business practices.
“This ESG update marks an important early chapter for the new Bespak,” said Chris Hirst, CEO of Bespak. “It reflects the work we’ve done to begin embedding sustainability across the business, from product design and operations to the way we partner with customers and suppliers while planning for the future.”
